U.S. Markets open in 4 hrs 25 mins

7 Biotech ETFs That Should Remain Healthy

Todd Shriber

The healthcare sector is struggling this year. In 2018, the group was the best-performing sector in the S&P 500. This year, it’s the worst. The Dow Jones U.S. Health Care Index is up just 10.20% year-to-date, but there are some pockets of strength and potential growth opportunities in the S&P 500’s third-largest sector weight.

Source: Shutterstock

Biotechnology is one of those groups. Some biotech ETFs aren’t setting the market ablaze this year, but broadly speaking, biotech ETFs are outperforming diversified healthcare funds. For example, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), the largest biotech ETF by assets, is up almost 10% year-to-date.

The current market environment, marked by lower interest rates and escalating trade tensions, could actually favor biotech ETFs due to the groups’ emphasis on the U.S. economy. Plus, the broader healthcare sector looks inexpensive relative to other defensive sectors.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

“Health care, the worst-performing sector this year, trades at 15 times forward earnings, below the 17 times multiple on the S&P 500. By comparison, staples, utilities and REITs trade closer to 20 times earnings,” reports CNBC.

Here are some biotech ETFs to consider right here, right now.


SPDR S&P Biotech ETF (XBI)

Expense ratio: 0.35% per year, or $35 on a $10,000 investment.

The SPDR S&P Biotech ETF (NYSEARCA:XBI) is home to $4.15 billion in assets under management, making it one of the largest biotech ETFs, but XBI’s size is not why it is being highlighted here. For active traders, XBI is worth a look right now because during the week starting Monday, Aug 5, half of XBI’s 119 holdings report earnings, so there are plenty of catalysts that could move this fund in the near term.

XBI is an equal weight ETF and as such tilts toward smaller biotech names as highlighted by an average market value of $10.6 billion for the fund’s components, putting it in mid-cap territory. XBI status as an imminent earnings play is relevant because FactSet expects second-quarter earnings for the healthcare sector to rise an average of 2.1%, the second-best growth rate among the 11 S&P 500 sectors.

What could be a challenge for XBI and other biotech ETFs over the near term is campaign-trail chatter about drug prices (many XBI components are considered pharmaceuticals makers), but in the fund’s corner are decent valuations and status of many of its holdings as credible takeover targets.


Invesco Dynamic Biotechnology & Genome ETF (PBE)

Source: Shutterstock

Expense ratio: 0.59%

The Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE) is an ideal biotech ETF for investors looking for a smart beta approach to the space. PBE, which turned 14 years old in June, tracks the Dynamic Biotech & Genome Intellidex Index.

That benchmark “is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value,” according to Invesco.

Smart beta is not always perfect, but its applications in the biotech ETF space are notable. Over the past three years, PBE has beaten a major cap-weighted index of biotechnology stocks by a margin of better than 3-to-1 with only slightly higher volatility.


ALPS Medical Breakthroughs ETF (SBIO)

Source: Shutterstock

Expense ratio: 0.50% per year

The ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) has long been a unique alternative to traditional biotech ETFs and with its emphasis on small-cap and smaller mid-cap stocks, SBIO can also be an alternative for risk-tolerant investors looking to replace standard small equity exposure.

In addition to capping components’ market values at the time of entry at $5 billion, SBIO’s underlying index requires that those companies have at least one drug or therapy in Phase II or III Food and Drug Administration (FDA) trials. So while there can be no guarantees that SBIO holdings will become the next Amgen or Gilead, at least investors know the fund is not chock full of financially flimsy fly-by-night biotech stocks.

And speaking of finances, SBIO components must have enough cash to survive at least two years to be included in the fund. That’s a stiffer requirement than is found on standard small-cap ETFs, perhaps explaining why over the past three years SBIO is not just one of the best biotech ETFs, but one of the best small-cap funds, too.


Global X Genomics & Biotechnology ETF (GNOM)

Source: Shutterstock

Expense ratio: 0.68%

Having debuted in April, the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) is one of the newest biotech ETFs on the market. Rookie status aside, this Global X fund addresses a compelling, fast-growing corner of the healthcare market.

“There are several segments within the genomics field that stand to benefit from falling genetic testing costs, the rise of precision medicine ever-increasing amounts of genetic data, and other trends fueling genomics’ disruption of health care,” according to Global X research.

As an industry, genomics is not nearly as old some other healthcare groups, but the upside of that is that the industry offers plenty of growth potential via areas such as gene sequencing, gene editing, computational genomics and genetic diagnostics and more. Home to 40 stocks, a decent-sized lineup for a niche ETF like this, GNOM touches many of the exciting corners of the genomics investment thesis.


ROBO Global Healthcare Technology and Innovation ETF (HTEC)

Source: Shutterstock

Expense ratio: 0.68%

Having debuted in late June, the ROBO Global Healthcare Technology and Innovation ETF (NYSEARCA:HTEC) is the newest of biotech ETFs highlighted here and to be clear, it is not a dedicated biotech ETF. Rather, HTEC is designed as a play on the themes of healthcare disruption and innovation, but that can and should some biotechnology exposure. HTEC targets the ROBO Global Healthcare Technology and Innovation Index.

“We anticipate that this technology revolution should profoundly transform the healthcare industry, offering a potential opportunity to investors over the next decade,” according to ROBO Global. “It is about shifting the model from caring for the sick to one of prevention, prediction and eradication of diseases. It is about enhancing physicians’ accuracy and therapies’ efficacy. Finally, it is about lowering costs. The expected result: longer, healthier lifespans.”

HTEC has a broad lineup at 85 components, but a good percentage of those names dwell in the genomics and pharmaceuticals arenas, giving this fund some credibility as a biotech ETF. Importantly, the intersection of healthcare and artificial intelligence (AI), one of HTEC’s points of emphasis, is real and growing.

“A.I. in health care could balloon to a $6.6 billion industry by 2021 form the $600 million back in 2014. A.I. funding has almost doubled to $2.3 billion in 2018, compared to $1.2 billion in 2017,” according to ETF Trends.


ARK Genomic Revolution Multi-Sector ETF (ARKG)

Source: Shutterstock

Expense ratio: 0.75%

For those looking for active management with their genomics investments, an advisable strategy in many instances, the ARK Genomic Revolution Multi-Sector ETF (NYSEARCA:ARKG) is one of the best funds to consider.

“Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business,” according to ARK Investment Management.

ARKG usually holds 30 to 50 stocks, but the fund typically spans into a half dozen fast-growing corners of the biotech space, including CRISPIR, bioinformatics, molecular diagnostics and more.

Past performance is never a guarantee of future returns, but the ARK team are excellent stock pickers. Over the past three years, ARKG is beating the largest biotech ETF by a margin of more than 8-to-1.


Invesco S&P SmallCap Health Care ETF (PSCH)

Source: Shutterstock

Expense ratio: 0.29%

The Invesco S&P SmallCap Health Care ETF (NASDAQ:PSCH) is an almost biotech ETF. “Almost” because as its name implies, it’s a diverse healthcare ETF, but when small-cap and healthcare stocks come together, biotechnology is usually involved.

PSCH confirms as much as nearly 29% of its holdings, its largest industry weight, are biotechnology names. Earlier, I mentioned that healthcare stocks are trading at attractive valuations, but that’s not the case with PSCH, which trades at 34x earnings. However, for investors that can stomach the added volatility, PSCH is worth the lofty multiples.

Over the past three years, this biotech ETF was 320 basis points more volatile than the S&P SmallCap 600 Index, but the Invesco funds outperformed that index by nearly 2-to-1.

Todd Shriber does not own any of the aforementioned securities.

More From InvestorPlace

The post 7 Biotech ETFs That Should Remain Healthy appeared first on InvestorPlace.

  • Coronavirus and Mideast tensions aren’t the stock market’s biggest problems this week, strategist warns
    Business
    MarketWatch

    Coronavirus and Mideast tensions aren’t the stock market’s biggest problems this week, strategist warns

    He said the S&P 500 (SPX)could see a pullback of as much as 5%. Stocks are relatively priced for perfection, and you tend to have a bit of an overreaction to bad news or in-line news when that happens,” he continued. With a crowded slate of earnings on tap, Hogan warned that it will probably be the biggest winners getting the biggest haircuts.

  • How the stock market has performed during past viral outbreaks, as epidemic locks down 16 Chinese cities
    World
    MarketWatch

    How the stock market has performed during past viral outbreaks, as epidemic locks down 16 Chinese cities

    According to Dow Jones Market Data, the S&P 500 posted a gain of 14.59% after the first occurrence of SARS back in 2002-03, based on the end of month performance for the index in April, 2003. About 12 months after that point, the broad-market benchmark was up 20.76% (see attached table): SARS resulted in a total of about 8,100 people being sickened during the 2003 outbreak, with 774 people dying, according to data from WHO and the Centers for Disease Control and Prevention. Separately, the S&P 500 rose 11.66% in the roughly six months following reports of the 2006 Avian flu virus — a fast-moving pathogen also known as H5N1.

  • One of the most successful stock-market investors says these 3 events ‘would definitely trigger a bear market’
    Business
    MarketWatch

    One of the most successful stock-market investors says these 3 events ‘would definitely trigger a bear market’

    Stanley Druckenmiller, one of Wall Street's most successful investors, acknowledges that the markets are riding high and that investors may be able to finally breathe freely in the short term after a number of shocks, but says investors should be wary of three events that could knock assets into a bear market. One of the reasons I'm pretty sanguine right now is I think we're close enough to the election, at least we can breathe for a few months,” he told Bloomberg Television during a recent interview. But there are a trio of situations that could upend that optimism — and perhaps permanently.

  • Virus Fears Drive Sell-Off in Stocks, Oil, Yuan: Markets Wrap
    Business
    Bloomberg

    Virus Fears Drive Sell-Off in Stocks, Oil, Yuan: Markets Wrap

    Major Asian markets were closed for holidays with the exception of those in India and Japan, where stocks slumped and the yen climbed. With the main Shanghai market closed, futures on Chinese shares and a London-listed iShares China ETF both fell more than 5%. The yuan erased this month's trade-deal driven gains in the wake of news that the virus continues to spread, with no peak in sight.

  • U.S. Index Futures Slide as Virus Spread Saps Risk Demand
    Business
    Bloomberg

    U.S. Index Futures Slide as Virus Spread Saps Risk Demand

    S&P 500 Index futures contracts expiring in March fell as much as 1.3% as of 8:50 a.m. in London, after China extended the Lunar New Year holiday for an unspecified period of time to help stem the spread of the coronavirus that has killed at least 80 people. Italy's FTSE MIB Index outperformed after Matteo Salvini, leader of the anti-immigrant League party, suffered a defeat in a key regional vote. President Xi Jinping on Saturday ordered a faster response to the viral outbreak, sending teams into hard-hit areas to push local officials to strengthen prevention and containment.

  • Adam Schiff's Closing Remarks at Impeachment Trial Disturbs Some GOP Senators
    Politics
    Meredith Videos

    Adam Schiff's Closing Remarks at Impeachment Trial Disturbs Some GOP Senators

    Senate Republicans said lead impeachment prosecutor Adam Schiff insulted them during the trial by repeating an anonymously sourced report that the White House had threatened to punish Republicans who voted against President Donald Trump.

  • This basket of dividend growth stocks can help your portfolio stand out in 2020
    Business
    MarketWatch

    This basket of dividend growth stocks can help your portfolio stand out in 2020

    Analysts at Goldman Sachs are highlighting a “dividend growth basket” of stocks at a time when valuations for the U.S. stock market have shot up to their second-highest level since June 2002. In the firm's recent “U.S. Weekly Kickstart” report Jan. 3, the analysts, led by David Kostin, recommended investors be cautious and look for “growth at a reasonable price,” but also included a group of dividend stocks with low price-to-earnings valuations relative to the S&P 500 (SPX) that also appear likely to continue raising their dividend payouts more quickly than the broader market.

  • Toll Brothers gears up to sell 2,200 homes in the West Valley
    Business
    American City Business Journals

    Toll Brothers gears up to sell 2,200 homes in the West Valley

    The 780-acre community includes 13 model homes and three community pools. It also will include an 18-hole Jack Nicklaus-designed private golf facility, which is the first golf course to be built in the West Valley in nearly a decade. The golf course is expected to be completed by January 2021, with a 35,000-square-foot clubhouse to be completed soon after, said Ryan Stemsrud, general manager for Sterling Grove Golf Club.

  • Why the coronavirus outbreak could trigger a stock-market pullback
    Business
    MarketWatch

    Why the coronavirus outbreak could trigger a stock-market pullback

    However, the missing ingredient to temporarily halt the advance in the market has been a catalyst,” said Jeff deGraaf, chairman of Renaissance Macro Research, in a Friday note. U.S. stocks gave up early gains Friday, trading lower as the death toll in China mounted and after the Centers for Disease Control and Prevention confirmed a second case in the U.S. Cases have turned up in other countries as well, including Japan, Taiwan, South Korea and Singapore. The S&P 500 index (SPX) fell 0.9% Friday, for its biggest one-day loss since Oct. 8, while the Dow Jones Industrial Average (DJIA) 170.36 points, or 0.6%.

  • AMD earnings: Intel’s data-center surge will be a tough act to follow
    Business
    MarketWatch

    AMD earnings: Intel’s data-center surge will be a tough act to follow

    Advanced Micro Devices Inc.'s sales of server chips may get heightened scrutiny following a surprise jump in data-center sales reported by larger rival Intel Corp. AMD (AMD) shifted the power balance against bigger rival Intel Corp. (INTC) last year as it released its 7-nm “Rome” chips while Intel failed to bring its 10-nm chip to the market. AMD's forceful re-entry into the server business, which had been completely dominated by Intel for many years, was a big part of its turnaround.

  • Roth IRA Contributions with No Job?
    Business
    Investopedia

    Roth IRA Contributions with No Job?

    The internal Revenue Service (IRS) gets a little grumpy if you contribute to a Roth individual retirement account (IRA) without what it calls earned income. You don't necessarily need a formal job to contribute to a Roth IRA. Although it's not true in all cases, if you're paying taxes on any type of income from working, there's a good chance that you can make Roth IRA contributions.

  • 3 Monster Growth Stocks That Are Ready for the Next Leg Higher
    Business
    TipRanks

    3 Monster Growth Stocks That Are Ready for the Next Leg Higher

    With no price increases expected for three years and little to no competition anticipated from Novartis' recently released ADAKVEO antibody treatment for sickle cell disease, the analyst thinks the market opportunity is large. Bearing this in mind, she bumped up the price target from $120 to $143 in addition to maintaining her bullish call. To watch Moussatos' track record, click here) In terms of the rest of the Street, a majority of analysts also see GBT as a Buy, 13 out of 16 to be exact.

  • Intel Corporation Just Beat EPS By 7.8%: Here's What Analysts Think Will Happen Next
    Business
    Simply Wall St.

    Intel Corporation Just Beat EPS By 7.8%: Here's What Analysts Think Will Happen Next

    It's been a pretty great week for Intel Corporation (NASDAQ:INTC) shareholders, with its shares surging 15% to US$68.47 in the week since its latest full-year results. The result was positive overall - although revenues of US$72b were in line with what analysts predicted, Intel surprised by delivering a statutory profit of US$4.71 per share, modestly greater than expected. Analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of.

  • Young trader’s epic Beyond Meat stock misfire: ‘Biggest mistake of my life’
    Business
    MarketWatch

    Young trader’s epic Beyond Meat stock misfire: ‘Biggest mistake of my life’

    For veteran Wall Street types, $12,000 is a rounding error, but for a guy getting his feet wet in the options pits, losing that much will leave a scar. Unfortunately, that's what happened this week to an anonymous trader whom we'll call “Juice,” if the sob story he shared on Reddit is accurate. “I thought I'd give options a try because I was doing pretty well swing trading and it was probably the biggest mistake of my life,” he wrote in a post.

  • Business
    Barrons.com

    A Giant Fund Sold Apple and Costco Stock. Here’s What It Bought.

    Dutch pension giant PGGM made some major moves in its U.S.-traded stock investments. In the fourth quarter, PGGM initiated a stake in (V) stock (ticker: V), and tripled its investment in (MSFT) stock (MSFT). PGGM disclosed the trades, among others, in a form it filed with the Securities and Exchange Commission.

  • Business
    Financial Times

    Five things to watch out for in Apple’s earnings

    The rally leaves expectations high for the company's first-quarter results on Tuesday, with analysts projecting that slightly lower sales for the iPhone, iPad, Mac and MacBook will be offset by faster growth in services and wearables. The holiday period is Apple's most important quarter by far. Apple is expected to report revenues up almost 5 per cent to $88.1bn, just shy of its record high two years ago.

  • No Survivors in Helicopter Crash That Killed Kobe Bryant, Eight Others
    News
    WSJ

    No Survivors in Helicopter Crash That Killed Kobe Bryant, Eight Others

    Kobe Bryant, the former Los Angeles Lakers superstar, died in a helicopter crash on Sunday, NBA officials confirmed to league employees. He was 41 years old. Bryant's 13-year-old daughter, Gianna, was also killed in the crash.

  • Tesla will mark the beginning of the end for this bull market, warns Ralph Nader
    Business
    MarketWatch

    Tesla will mark the beginning of the end for this bull market, warns Ralph Nader

    Apparently so, according to consumer advocate and former presidential candidate Ralph Nader, who issued a stark warning this week, not only on the electric-car maker's pricey stock, but on the stock market as a whole. “Deep in debt, selling less than 400,000 vehicles last year and challenged by several competing electric car models in 2020, Tesla's stock valuation stunningly exceeds VW which sold over 10 million vehicles last year,” Nader added in a follow-up tweet. Of course, his stance didn't sit well with Tesla fans.

  • Head of U.S.’ largest bank says central banks are fueling a sovereign debt bubble, negative-rates won’t ‘end well’
    Business
    MarketWatch

    Head of U.S.’ largest bank says central banks are fueling a sovereign debt bubble, negative-rates won’t ‘end well’

    Jamie Dimon doesn't have much positive to say about negative interest rates in Europe and Japan or public policy in the United States during the past decade. The JPMorgan Chase & Co. (JPM) Chairman and CEO blasted the policy of negative interest rates adopted in Europe and Japan during an interview with CNBC, while arguing that economic growth in the U.S. could have been nearly double its actual rate if the government policy had been better. Dimon took aim at fiscal and other economic policies in place at the U.S. federal level.

  • Norway tells Toyota to stop calling hybrid cars “self-charging”
    Business
    Quartz

    Norway tells Toyota to stop calling hybrid cars “self-charging”

    Toyota pioneered the hybrid-electric Prius in 1997, but it has steered clear of developing all-electric cars. Executive vice-president Shigeki Terashi said last June that the company's policy toward battery-electric vehicles hasn't changed, citing a limited supply of batteries. “We are not shifting our focus to prioritize battery EVs, nor are we abandoning our [hydrogen fuel cell] strategy,” he said.

  • Pfizer Inc. (NYSE:PFE) Looks Interesting, And It's About To Pay A Dividend
    Business
    Simply Wall St.

    Pfizer Inc. (NYSE:PFE) Looks Interesting, And It's About To Pay A Dividend

    Dividends are usually paid out of company profits, so if a company pays out more than it earned then its dividend is usually at greater risk of being cut. That's why it's good to see Pfizer paying out a modest 49% of its earnings. That said, even highly profitable companies sometimes might not generate enough cash to pay the dividend, which is why we should always check if the dividend is covered by cash flow.

  • Amazon hits $200 billion mark beating Google and Apple to become world’s most valuable brand
    Business
    MarketWatch

    Amazon hits $200 billion mark beating Google and Apple to become world’s most valuable brand

    Amazon (AMZN)  has beaten Google (GOOG) Apple (AAPL) and Microsoft (MSFT) to become the world's most valuable brand, according to a global report. The value of the e-commerce giant's brand has soared 17.5% to a record $220.8 billion - the first brand to top $200 billion - the Brand Finance Global 500 index found. Google, which comes second, also climbed in value, while third-placed Apple and fourth-placed Microsoft saw their brand values dip.

  • QQQ vs. TQQQ: What's the Difference?
    Business
    Investopedia

    QQQ vs. TQQQ: What's the Difference?

    QQQ vs. TQQQ: An Overview With the Nasdaq Composite soaring to record heights and the technology sector ranking as this year's best-performing group, it is not surprising that many investors are evaluating technology and Nasdaq-related exchange-traded funds (ETFs). The Invesco QQQ is an exchange-traded fund (ETF) that is widely held and tracks the Nasdaq 100 Index. Its focus is on large international and U.S. companies in the technology, health care, industrial, consumer discretionary, and telecommunications sectors.

  • Founder of world’s largest hedge fund says ‘cash is trash’ as the Dow soars to records
    Business
    MarketWatch

    Founder of world’s largest hedge fund says ‘cash is trash’ as the Dow soars to records

    If there are investors who believe cash is king amid this market bull run, they ought to think again, suggests Ray Dalio. The billionaire founder of the hedge fund Bridgewater Associates said during a CNBC interview on Tuesday on the sidelines of the World Economic Forum in Davos, Switzerland, that investors should be buying this market, rather than seeking safety in cash. “Cash is trash,” said the hedge-fund luminary, who founded Westport, Conn.–based Bridgewater in 1975.

  • Microsoft earnings preview: Cloud business has nothing but blue skies
    Business
    MarketWatch

    Microsoft earnings preview: Cloud business has nothing but blue skies

    It may sound like a broken record, but Microsoft Corp. continues to do just that: break financial records. When the software behemoth (MSFT) reports its results Wednesday, Wall Street is ready for another strong quarter. Indeed, after a strong 2019 in which its market valuation surged past $1 trillion, expect more of the same in 2020 and beyond from Microsoft, Evercore ISI analyst Kirk Materne said in a Jan. 22 note that maintains an Outperform rating and price target of $180.